Sterilization-products maker STERIS Corp. has signed a development agreement with a New Jersey firm that specializes in filtration products.
STERIS and River Edge, N.J.-based Nephros Inc. “will jointly develop filtration-based products for medical device applications,” according to a statement from Nephros. The statement doesn’t get any more specific than that and Stephen Norton, a STERIS spokesman, declined to elaborate.
“For competitive reasons, no additional details are available, beyond stating that the agreement involves collaboration on general research projects,” Norton said in an e-mail. A Nephros spokeswoman didn’t return a call.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The deal calls for an initial payment from STERIS to Nephros, and Nephros could receive additional payments if it hits unspecified product-development milestones.
“I would characterize the size of the payments as small and not material to STERIS,” Norton wrote. “The investment is material to Nephros and they were required to disclose the agreement.”
Nephros specializes in the chronic renal disease market, selling products designed to filter from the blood harmful substances that often aren’t removed by existing methods of dialysis. Patients suffering from chronic renal, or kidney, disease often are treated with dialysis, which involves a machine that removes a patient’s blood, filters out harmful substances and returns it to the patient’s body.
Nephrons are filtering units found in the kidneys. About a million are present in each kidney.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In July 2009, Nephros received federal regulatory approval to begin selling its “Dual Stage Ultrafilters,” which are used to filter out biological contaminants from water used in dialysis procedures. In August, it received a $2 million contract from the U.S. Navy to develop a dual-stage water-purifying filter.
Like Nephros, STERIS is no stranger to military contracts. Last year, STERIS obtained a $6 million research-and-development grant from the U.S. Department of Defense. The company is using the grant to study and develop a system that would sterilize and decontaminate military aircraft after exposure to biological weapons, and examine ways to prevent infections acquired in military hospitals.
Nephros is publicly traded on the over-the-counter stock market and was founded in 1997 by Columbia University scientists.
